Foretinib
- Generic Name
- Foretinib
- Drug Type
- Small Molecule
- Chemical Formula
- C34H34F2N4O6
- CAS Number
- 849217-64-7
- Unique Ingredient Identifier
- 81FH7VK1C4
- Background
Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits the activation of MET, RON, ERK and AKT, decreased proliferation and increased apoptosis.
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02034097
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 47
- Registration Number
- NCT01147484
- Locations
- 🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 19
- Registration Number
- NCT01138384
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
- Conditions
- Lung Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 31
- Registration Number
- NCT01068587
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
🇨🇦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00920192
- Locations
- 🇹ðŸ‡
GSK Investigational Site, Khon Kaen, Thailand
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00742131
A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00742261
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 74
- Registration Number
- NCT00726323
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.